Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于13% 概率
$11,314 交易量
$11,314 交易量
2026-10-06
13% 概率
$11,314 交易量
$11,314 交易量
2026-10-06
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市场开放时间： May 5, 2026, 8:02 PM ET
交易量
$11,314结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETThis market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,314结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETEli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题